Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19-Reference-Cited by-同舟云学术

Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19

Published:2022-10-01 Issue:6 Volume:11 Page:2125-2139
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Jalbert Jessica J.,Hussein Mohamed,Mastey Vera,Sanchez Robert J.,Wang Degang,Murdock Dana,Fariñas Laura,Bussey Jonathan,Duart Carlos,Hirshberg Boaz,Weinreich David M.,Wei Wenhui

Funder

Regeneron Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40121-022-00691-z.pdf

Reference47 articles.

1. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2020;384(3):238–51.

2. Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021;385(23):e81.

3. Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632–44.

4. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941–50.

5. O’Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med. 2021;385(13):1184–95.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of casirivimab and imdevimab for preventing and treating COVID-19: a systematic review and meta-analysis;Journal of Thoracic Disease;2024-06

2. Predictive Assessment of the Antiviral Properties of Imperata cylindrica against SARS‐CoV‐2;Advances in Virology;2024-01

3. CLINICAL EFFECTIVENESS OF CASIRIVIMAB AND IMDEVIMAB COMPARED WITH STANDARD OF CARE IN COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS;Studies in Medical Sciences;2024-01-01

4. Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19;Clinical and Experimental Medicine;2023-02-13

5. Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19;2023-01-09